| abstract |
An object of the present invention is to provide a therapeutic agent for hypoglycemia, which has few side effects such as hypoglycemia disorder of existing insulin or insulin secretagogue and is effective for diabetes. A therapeutic agent for diabetes comprising a cyclin-dependent kinase (Cdk) 5 inhibitor, particularly a therapeutic agent for diabetes comprising olomoucine, roscovitine, pervalanol A or an analog thereof. An insulin secretagogue comprising a Cdk5 inhibitor, particularly an insulin secretagogue comprising olomoucine, roscovitine, pervalanol A or an analog thereof. [Selection diagram] None |